Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Novavax (NASDAQ:NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

The threat of another influenza pandemic arising from bird-to-human and then human-to-human transmission drives continuing efforts to develop effective vaccines against avian influenza. In the latest ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

Topline Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new ...

Novavax stock has plummeted from $290 a share in February 2021 to around $50 recently. The FDA finally appears poised to authorize the company's vaccine, however.

Why Novavax’s vaccine was authorized 2 years into the pandemic Novavax CEO Stanley Erck discusses his company’s COVID-19 vaccine, which was authorized by the FDA this week.